Merus Investor Relations Material

Merus N.V. is a clinical-stage immuno-oncology company focused on developing innovative bispecific antibody therapeutics. The company specializes in creating full-length human multispecific antibodies known as Biclonics and Triclonics, which are designed to engage multiple targets, offering new approaches to treat various cancers. Merus has a broad pipeline, including candidates in different stages of clinical trials targeting solid tumors and hematologic malignancies. The company is headquartered in Utrecht, Netherlands, and its shares are listed on the Nasdaq.